MARIPOSA
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
MARIPOSA
Jun 1, 2024, 12:55 |
Societies
Day 1 ASCO24 Highlights by Oncology Brothers
Oncology Brothers shared on X: Day 1 ASCO24 Highlights: 1. CROWN: Lorlatinib in ALK mNSCLC…
May 29, 2024, 12:03 |
Insight
Eric Singhi: MARIPOSA a path forward to help us determine who benefits from 1L combination therapy?
Eric Singhi shared on X: "MARIPOSA: Amivantamab + lazertinib v osimertinib in 1L EGFR+ mNSCLC:…
Apr 21, 2024, 18:13 |
Blog
Antonio Passaro: An intense yet incredibly rewarding day in Oporto
Antonio Passaro, Medical Director with Highly Specialized Position at IEO European Institute of Oncology, shared a…
All:
3
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube